Aandeelhouders goedkeuring alle resoluties op de agenda
EINDHOVEN, Nederland & LAUSANNE, Zwitserland–(BUSINESS WIRE)– DIT PERSBERICHT BEVAT INFORMATIE IN DE ZIN VAN ARTIKEL 7(1) VAN DE EUROPESE MARKTMISBRUIKVERORDENING (596/2014).
ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën ontwikkelt om de beweging, de onafhankelijkheid en de gezondheid van mensen met een dwarslaesie te herstellen, kondigt vandaag alle voorgestelde resoluties aan tijdens haar jaarlijkse Algemene Vergadering van Aandeelhouders (AVA), die vanmorgen werd gehouden in Amsterdam, Nederland om 10.00 uur CEST, naar behoren zijn goedgekeurd. De volledige details van de tijdens de AVA goedgekeurde besluiten zijn te vinden op de Investor Relations-website van ONWARD.
Voor meer informatie over ONWARD’s ARC Therapy en de visie van het bedrijf om beweging, onafhankelijkheid en gezondheid te herstellen bij mensen met een dwarslaesie, kunt u terecht op ONWD.com.
ONWARD Announces Results of Annual General Meeting of Shareholders
Shareholders approval all resolutions on the agenda
EINDHOVEN, the Netherlands & LAUSANNE, Switzerland–(BUSINESS WIRE)– THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014).
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announces all proposed resolutions at its Annual General Meeting of Shareholders (AGM), held this morning in Amsterdam, the Netherlands at 10.00a CEST, were duly passed. The full details of the resolutions approved during the AGM can be found on ONWARD’s Investor Relations website.
To learn more about ONWARD’s ARC Therapy and the company’s vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.
ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed spinal-cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company’s first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide. The company completed first-in-human use of its ARCIM neurostimulator in May 2022.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains an office in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
For Company Enquiries:
For Media Enquiries:
For Investor Enquiries: